Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. On the Frontlines of IgA Nephropathy

Advances in IgAN: New Frontiers in Biomarkers and Treatment

ReachMD Healthcare Image
Restart
Resume
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Comments
  • Overview

    IgA nephropathy (IgAN) is a common glomerulopathy characterized by a complex four-hit pathogenesis involving galactose-deficient IgA1, immune complex formation, and mesangial cell activation, leading to kidney damage. This understanding of its pathogenesis has led to the identification of biomarkers that predict disease progression as well as the development of targeted therapies that aim to slow that progression. Joining Dr. Gates Colbert to dive deeper into the current IgAN research is Dr. Edward Filippone, Professor of Medicine at Thomas Jefferson University in Philadelphia.

Recommended
Details
Presenters
Comments
  • Overview

    IgA nephropathy (IgAN) is a common glomerulopathy characterized by a complex four-hit pathogenesis involving galactose-deficient IgA1, immune complex formation, and mesangial cell activation, leading to kidney damage. This understanding of its pathogenesis has led to the identification of biomarkers that predict disease progression as well as the development of targeted therapies that aim to slow that progression. Joining Dr. Gates Colbert to dive deeper into the current IgAN research is Dr. Edward Filippone, Professor of Medicine at Thomas Jefferson University in Philadelphia.

Schedule14 Dec 2024